1. 251 Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus. (April 2019) Authors: Jordan, Jarrat; Sweet, Kristen; Cesaroni, Matteo; Ma, Keying; Franks, Carol; Seridi, Loqmane; Schreiter, Jessica; Gordon, Robert; Lipsky, Peter; Vollenhoven, Ronald van; Tsokos, George C; Hahn, Bevra H; Rose, Shawn; Baribaud, Frédéric; Loza, Matthew J; Campbell, Kim Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. (3rd October 2017) Authors: McBride, Ali; Campbell, Kim; Bikkina, Mohan; MacDonald, Karen; Abraham, Ivo; Balu, Sanjeev Journal: Journal of medical economics Issue: Volume 20:Number 10(2017) Page Start: 1083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework. Issue 8 (August 2021) Authors: Wang, Weijia; Li, Edward; Campbell, Kim; McBride, Ali; D'Amato, Steve Journal: JCO oncology practice Issue: Volume 17:Issue 8(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. (2nd August 2020) Authors: McBride, Ali; Wang, Weijia; Campbell, Kim; Balu, Sanjeev; MacDonald, Karen; Abraham, Ivo Journal: Journal of medical economics Issue: Volume 23:Number 8(2020) Page Start: 856 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. Issue 1 (10th February 2020) Authors: Helliwell, Philip S; Gladman, Dafna D; Chakravarty, Soumya D; Kafka, Shelly; Karyekar, Chetan S; You, Yin; Campbell, Kim; Sweet, Kristen; Kavanaugh, Arthur; Gensler, Lianne S Journal: RMD open Issue: Volume 6:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Evaluation of a fit-for-purpose assay to monitor antigen-specific functional CD4+ T-cell subpopulations in rheumatoid arthritis using flow cytometry–based peptide-MHC class-II tetramer staining. (5th December 2021) Authors: Patel, Swati; Ramnoruth, Nishta; Wehr, Pascale; Rossjohn, Jamie; Reid, Hugh H; Campbell, Kim; Nel, Hendrik J; Thomas, Ranjeny Journal: Clinical and experimental immunology Issue: Volume 207:Number 1(2022) Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. (October 2017) Authors: McBride, Ali; Balu, Sanjeev; Campbell, Kim; Bikkina, Mohan; MacDonald, Karen; Abraham, Ivo Journal: Future oncology Issue: Volume 13:Number 25(2017) Page Start: 2285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. (October 2017) Authors: McBride, Ali; Balu, Sanjeev; Campbell, Kim; Bikkina, Mohan; MacDonald, Karen; Abraham, Ivo Journal: Future oncology Issue: Volume 13:Number 25(2017) Page Start: 2285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. (2nd January 2020) Authors: McBride, Ali; Krendyukov, Andriy; Mathieson, Nicola; Campbell, Kim; Balu, Sanjeev; Natek, Maja; MacDonald, Karen; Abraham, Ivo Journal: Journal of medical economics Issue: Volume 23:Number 1(2020) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review. Issue 7 (3rd July 2022) Authors: Campbell, Kim; Chadha, Nidhi; Dimri, Seema; Wang, Weijia; Li, Edward Journal: Expert review of hematology Issue: Volume 15:Issue 7(2022) Page Start: 619 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗